Astellas Pharma Operating Income 2012-2019 | ALPMY

Astellas Pharma annual/quarterly operating income history and growth rate from 2012 to 2019. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Astellas Pharma operating income for the quarter ending September 30, 2019 was $M, a 100% decline year-over-year.
  • Astellas Pharma operating income for the twelve months ending September 30, 2019 was $1.678B, a 32.12% decline year-over-year.
  • Astellas Pharma annual operating income for 2019 was $2.195B, a 9.16% increase from 2018.
  • Astellas Pharma annual operating income for 2018 was $2.011B, a 13.65% decline from 2017.
  • Astellas Pharma annual operating income for 2017 was $2.329B, a 12.7% increase from 2016.
Astellas Pharma Annual Operating Income
(Millions of US $)
2019 $2,195
2018 $2,011
2017 $2,329
2016 $2,067
2015 $1,690
2014 $1,132
2013 $1,637
2012 $1,604
2011 $11,791
2010 $10,519
2009 $9,947
2008 $9,395
2007 $7,650
2006 $7,993
Astellas Pharma Quarterly Operating Income
(Millions of US $)
2019-09-30
2019-06-30 $701
2018-06-30 $585
2017-06-30 $392
2016-09-30 $629
2016-06-30 $864
2016-03-31 $298
2015-12-31 $681
2015-09-30 $580
2015-06-30 $508
2015-03-31 $176
2014-12-31 $514
2014-09-30 $504
2014-06-30 $496
2014-03-31
2013-12-31
2013-09-30
2013-06-30 $389
2013-03-31
2012-12-31
2012-09-30
2012-06-30 $661
2012-03-31
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $27.558B $11.834B
Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment of atopic dermatitis in the topical immunomodulator class, Harnal to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder and Fungard an antifungal agent. Astellas Pharma, Inc. is headquartered in Tokyo, Japan.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $54.432B 31.49
Takeda Pharmaceutical (TAK) Japan $45.999B 8.06
Eisai (ESALY) Japan $19.334B 36.02
UCB SA (UCBJF) Belgium $15.687B 0.00
Grifols, S.A (GRFS) Spain $13.187B 16.39
Merck (MKGAF) Germany $12.536B 16.44
Ono Pharmaceutical (OPHLF) Japan $9.254B 19.78
Neurocrine Biosciences (NBIX) United States $7.917B 219.95
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $7.874B 0.00
Catalent (CTLT) United States $7.164B 29.48
Ionis Pharmaceuticals (IONS) United States $6.754B 20.47
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.361B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $5.544B 6.76
Orion OYJ (ORINY) Finland $5.269B 23.61
STADA ARZNEIMI (STDAF) Germany $4.685B 0.00
Forty Seven (FTSV) United States $4.597B 0.00
IPSEN SA ADR (IPSEY) France $4.543B 0.00
United Therapeutics (UTHR) United States $4.070B 0.00
Evotec AG (EVTCY) Germany $3.428B 55.29
Hypermarcas (HYPMY) Brazil $3.424B 10.41
Nektar Therapeutics (NKTR) United States $2.994B 0.00
FibroGen (FGEN) United States $2.866B 0.00
PTC Therapeutics (PTCT) United States $2.666B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $2.655B 49.28
Taro Pharmaceutical Industries (TARO) Israel $2.418B 9.78
ChemoCentryx (CCXI) United States $2.402B 0.00
Xencor (XNCR) United States $1.649B 67.35
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.620B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.561B 18.98
Theravance Biopharma (TBPH) Cayman Islands $1.439B 0.00
Sage Therapeutics (SAGE) United States $1.347B 0.00
USANA Health Sciences (USNA) United States $1.344B 14.11
Corcept Therapeutics (CORT) United States $1.335B 14.94
Pacira Pharmaceuticals (PCRX) United States $1.295B 35.40
Karyopharm Therapeutics (KPTI) United States $1.168B 0.00
Heron Therapeutics (HRTX) United States $1.056B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.010B 31.30
Zogenix (ZGNX) United States $1.010B 0.00
Akebia Therapeutics (AKBA) United States $0.874B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $0.859B 11.96
Esperion Therapeutics (ESPR) United States $0.846B 0.00
CLINIGEN GP (CLIGF) United Kingdom $0.781B 0.00
Endo (ENDP) Ireland $0.721B 1.33
ImmunoGen (IMGN) United States $0.596B 0.00
Tilray (TLRY) Canada $0.576B 0.00
Translate Bio (TBIO) United States $0.572B 0.00
Aerie Pharmaceuticals (AERI) United States $0.565B 0.00
Molecular Templates (MTEM) United States $0.561B 0.00
Collegium Pharmaceutical (COLL) United States $0.553B 0.00
Radius Health (RDUS) United States $0.550B 0.00
Portola Pharmaceuticals (PTLA) United States $0.504B 0.00
Indivior (INVVY) United States $0.397B 2.36
Siga Technologies (SIGA) United States $0.393B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.386B 15.84
Innate Pharma SA (IPHYF) France $0.385B 0.00
Ardelyx (ARDX) United States $0.378B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.365B 12.17
Corbus Pharmaceuticals Holdings (CRBP) United States $0.354B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.324B 0.00
Organogenesis Holdings (ORGO) United States $0.312B 0.00
Trillium Therapeutics (TRIL) Canada $0.301B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.301B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.299B 0.00
Calithera Biosciences (CALA) United States $0.286B 0.00
Lannett Co Inc (LCI) United States $0.285B 4.58
Harpoon Therapeutics (HARP) United States $0.277B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.263B 0.00
DURECT (DRRX) United States $0.260B 0.00
Flexion Therapeutics (FLXN) United States $0.256B 0.00
Ocular Therapeutix (OCUL) United States $0.251B 0.00
TherapeuticsMD (TXMD) United States $0.250B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.246B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.243B 0.00
Concert Pharmaceuticals (CNCE) United States $0.232B 0.00
Rafael Holdings (RFL) United States $0.186B 0.00
CASI Pharmaceuticals (CASI) United States $0.185B 0.00
Recro Pharma (REPH) United States $0.166B 0.00
OptiNose (OPTN) United States $0.164B 0.00
PROFOUND MEDICL (PROF) Canada $0.157B 0.00
MEI Pharma (MEIP) United States $0.155B 0.00
Jounce Therapeutics (JNCE) United States $0.145B 2.61
Nature's Sunshine Products (NATR) United States $0.140B 17.58
La Jolla Pharmaceutical (LJPC) United States $0.140B 0.00
Taiwan Liposome (TLC) Taiwan $0.137B 0.00
KalVista Pharmaceuticals (KALV) United States $0.135B 0.00
VAXART, INC (VXRT) United States $0.120B 0.00
Redhill Biopharma (RDHL) Israel $0.104B 0.00
CannTrust Holdings (CTST) Canada $0.090B 0.00
IMV INC (IMV) Canada $0.086B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.084B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.081B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.081B 0.00
Champions Oncology (CSBR) United States $0.080B 0.00
SCYNEXIS (SCYX) United States $0.079B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.074B 0.00
CTI BioPharma (CTIC) United States $0.070B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.068B 0.00
Biomerica (BMRA) United States $0.065B 0.00
CV Sciences (CVSI) United States $0.064B 0.00
Xeris Pharmaceuticals (XERS) United States $0.064B 0.00
Aquestive Therapeutics (AQST) United States $0.062B 0.00
Otonomy (OTIC) United States $0.060B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.056B 17.62
ALLERGY THERAPT (AGYTF) United Kingdom $0.055B 0.00
Nivalis Therapeutics (ALPN) United States $0.054B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.052B 0.00
Onconova Therapeutics (ONTX) United States $0.048B 0.00
Infinity Pharmaceuticals (INFI) United States $0.047B 0.00
Aclaris Therapeutics (ACRS) United States $0.046B 0.00
PharmAthene (ALT) United States $0.045B 0.00
GTx (ONCT) United States $0.044B 0.00
Natural Alternatives (NAII) United States $0.043B 19.47
MediWound (MDWD) Israel $0.040B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.040B 133.57
Sundial Growers (SNDL) Canada $0.040B 0.00
Iterum Therapeutics (ITRM) Ireland $0.036B 0.00
Neos Therapeutics (NEOS) United States $0.036B 0.00
Forward Pharma (FWP) Denmark $0.035B 0.00
PolarityTE (PTE) United States $0.035B 0.00
ElectroCore (ECOR) United States $0.031B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.031B 0.00
Heat Biologics (HTBX) United States $0.029B 0.00
Jaguar Animal Health (JAGX) United States $0.026B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.024B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.023B 0.00
ProPhase Labs (PRPH) United States $0.022B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.021B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.021B 0.00
Cardiome Pharma (CORV) Canada $0.021B 0.00
Lipocine (LPCN) United States $0.020B 0.00
Mannatechorporated (MTEX) United States $0.018B 5.78
Bio-Path Holdings (BPTH) United States $0.018B 0.00
Novan (NOVN) United States $0.018B 0.00
Cyanotech (CYAN) United States $0.013B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.012B 0.00
Shineco (TYHT) China $0.012B 0.00
China SXT Pharmaceuticals (SXTC) China $0.011B 0.00
Vical (BBI) United States $0.011B 0.00
KemPharm (KMPH) United States $0.010B 0.00
Regulus Therapeutics (RGLS) United States $0.010B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.009B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.007B 0.00
Midatech Pharma (MTP) United Kingdom $0.006B 0.00
HANCOCK JAFFE (HJLI) United States $0.006B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.006B 0.00
RXi Pharmaceuticals (PHIO) United States $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Flex Pharma (SLRX) United States $0.003B 0.00